Literature DB >> 7845667

Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.

S L Lessnick1, B S Braun, C T Denny, W A May.   

Abstract

The (11;22) chromosomal translocation found in Ewing's sarcoma and related tumors fuses the amino terminus of the EWS protein to the DNA-binding domain of the FLI-1 transcription factor. In contrast to normal FLI-1, the EWS/FLI-1 fusion transforms NIH3T3 cells and this activity requires both EWS and FLI-1 sequences. Reporter gene assays showed that the portion of EWS fused to FLI-1 encodes a strong transcriptional activation domain. To determine whether this function is necessary for transformation by EWS/FLI-1, deletion analysis of EWS was performed. We found that the EWS domain could be functionally subdivided into two regions: (i) an amino terminal domain (domain A) which transforms efficiently when fused to FLI-1 but has little transactivation activity in a model system and (ii) a distal region (domain B) which transactivates efficiently but transforms less efficiently when fused to FLI-1. Replacement of the EWS domain with known heterologous transcriptional activation domains yielded chimeric FLI-1 fusions that in some instances could transform NIH3T3 cells. Finally we demonstrate that EWS/FLI-1 and related FLI-1 chimeras are able to cooperate with another transcription factor to activate a model reporter gene. These results further demonstrate that EWS/FLI-1 is an aberrant transcription factor and suggest that the EWS domain mediates important protein-protein interactions with other factors resulting in the transcriptional modulation of target genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845667

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS).

Authors:  H Ichikawa; K Shimizu; R Katsu; M Ohki
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 3.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

4.  In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7.

Authors:  Roumiana Todorova
Journal:  Mol Biol Rep       Date:  2008-07-08       Impact factor: 2.316

Review 5.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

Review 6.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

7.  TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins.

Authors:  L Yang; L J Embree; D D Hickstein
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

8.  Is There a Predisposition Gene for Ewing's Sarcoma?

Authors:  R L Randall; S L Lessnick; K B Jones; L G Gouw; J E Cummings; L Cannon-Albright; J D Schiffman
Journal:  J Oncol       Date:  2010-03-15       Impact factor: 4.375

9.  Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma.

Authors:  Patrick P Lin; Yongxing Wang; Guillermina Lozano
Journal:  Sarcoma       Date:  2010-10-05

10.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.